patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_600449 | REC_0008201 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.4 | 80 | male | 2 | 3 | 4.2 | 4 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.871123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925012 | REC_0008202 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.7 | 79 | female | 1 | 12 | 6.2 | 2 | alectinib 600 mg BID | 26.7 | true | MSI-H | 2026-03-15T05:35:58.871433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120190 | REC_0008203 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.1 | 54 | female | 0 | 11 | 5.5 | 2 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:58.871803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630159 | REC_0008204 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.7 | 62 | male | 1 | 15 | 7.2 | 9 | entrectinib 600 mg daily | 9 | true | MSS | 2026-03-15T05:35:58.872349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857962 | REC_0008205 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 15.4 | 61 | female | 0 | 14 | 3.9 | 2 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:58.872667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602115 | REC_0008206 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.9 | 66 | female | 0 | 19 | 7 | 7 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:58.872989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617909 | REC_0008207 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 5.3 | 56 | male | 0 | 12 | 4.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 37.9 | true | MSS | 2026-03-15T05:35:58.873306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958240 | REC_0008208 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 10.1 | 75 | female | 1 | 7 | 8.1 | 6 | alectinib 600 mg BID | 15.6 | true | MSS | 2026-03-15T05:35:58.873567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203528 | REC_0008209 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9 | 67 | male | 1 | 20 | 5.5 | 5 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.873825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370561 | REC_0008210 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 14.8 | 66 | female | 1 | 14 | 6.6 | 1 | entrectinib 600 mg daily | 18.4 | true | MSI-H | 2026-03-15T05:35:58.874090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609341 | REC_0008211 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.3 | 64 | female | 0 | 47 | 5.4 | 4 | pembrolizumab 200 mg q3w | 5.6 | true | MSS | 2026-03-15T05:35:58.874392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968744 | REC_0008212 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 26 | 13 | 56 | male | 1 | 21 | 6.3 | 0 | entrectinib 600 mg daily | 45.9 | false | MSI-H | 2026-03-15T05:35:58.874842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403170 | REC_0008213 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.2 | 64 | male | 1 | 36 | 6.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 7.4 | false | MSS | 2026-03-15T05:35:58.875194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275430 | REC_0008214 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.2 | 48 | female | 0 | 8 | 6.2 | 6 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.875446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252746 | REC_0008215 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 9.9 | 74 | female | 1 | 17 | 4.3 | 2 | osimertinib 80 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:58.875693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202610 | REC_0008216 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.4 | 75 | female | 2 | 40 | 4.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 8.8 | true | MSS | 2026-03-15T05:35:58.875930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910445 | REC_0008217 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.4 | 66 | male | 0 | 21 | 6.1 | 5 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:58.876365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927004 | REC_0008218 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11 | 78 | female | 0 | 9 | 7.7 | 5 | sotorasib 960 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:58.876757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550968 | REC_0008219 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 15 | 67 | female | 1 | 20 | 8 | 5 | osimertinib 80 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:58.877010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168455 | REC_0008220 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 14.4 | 74 | female | 0 | 10 | 6.6 | 3 | osimertinib 80 mg daily | 18.7 | true | MSI-H | 2026-03-15T05:35:58.877249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940415 | REC_0008221 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.2 | 90 | male | 2 | 6 | 6.3 | 7 | entrectinib 600 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:58.877741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971014 | REC_0008222 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 7.2 | 72 | female | 2 | 16 | 4.1 | 7 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:58.878146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226113 | REC_0008223 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 2.2 | 67 | female | 0 | 18 | 6.6 | 4 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:58.878615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362874 | REC_0008224 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 13 | 70 | female | 2 | 15 | 6.1 | 0 | entrectinib 600 mg daily | 33.4 | false | MSI-H | 2026-03-15T05:35:58.879040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988986 | REC_0008225 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.9 | 69 | female | 0 | 46 | 3.9 | 2 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:35:58.879498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735621 | REC_0008226 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7 | 72 | female | 2 | 61 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 20.7 | false | MSS | 2026-03-15T05:35:58.879743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846137 | REC_0008227 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 12.4 | 53 | female | 0 | 13 | 6 | 0 | osimertinib 80 mg daily | 34.7 | true | MSI-H | 2026-03-15T05:35:58.880039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770326 | REC_0008228 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.2 | 80 | female | 2 | 78 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:58.880398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923815 | REC_0008229 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 15.8 | 59 | male | 0 | 18 | 5.8 | 6 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.880650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986508 | REC_0008230 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 12.3 | 69 | female | 1 | 21 | 5.6 | 1 | entrectinib 600 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:35:58.880984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527528 | REC_0008231 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 17 | 62 | female | 1 | 4 | 5.4 | 6 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:58.881228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641293 | REC_0008232 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 13.5 | 66 | female | 1 | 15 | 5 | 1 | entrectinib 600 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.881464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803767 | REC_0008233 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.1 | 68 | female | 0 | 13 | 4.7 | 1 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:35:58.881696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666006 | REC_0008234 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 33 | 10 | 72 | female | 0 | 23 | 5.3 | 0 | osimertinib 80 mg daily | 60 | true | MSS | 2026-03-15T05:35:58.881931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878521 | REC_0008235 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 13.7 | 69 | female | 0 | 12 | 6.1 | 2 | pembrolizumab 200 mg q3w | 25.4 | false | MSS | 2026-03-15T05:35:58.882161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161459 | REC_0008236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.6 | 56 | male | 1 | 14 | 3.1 | 2 | entrectinib 600 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:58.882390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118827 | REC_0008237 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.4 | 65 | female | 1 | 14 | 5.8 | 6 | entrectinib 600 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:58.882626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296868 | REC_0008238 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 13.8 | 66 | female | 1 | 9 | 5.8 | 3 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:58.882858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730781 | REC_0008239 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.1 | 68 | female | 0 | 22 | 4.2 | 4 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:58.883088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609485 | REC_0008240 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.3 | 57 | male | 0 | 22 | 6.2 | 4 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:58.883321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376433 | REC_0008241 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 10.5 | 52 | female | 0 | 0 | 5 | 4 | sotorasib 960 mg daily | 4.6 | false | MSS | 2026-03-15T05:35:58.883555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321771 | REC_0008242 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 15.8 | 62 | male | 0 | 29 | 5.2 | 6 | pembrolizumab 200 mg q3w | 8.7 | true | MSI-H | 2026-03-15T05:35:58.883791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984218 | REC_0008243 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 13.7 | 64 | male | 1 | 14 | 4.1 | 6 | osimertinib 80 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:58.884123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739739 | REC_0008244 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.1 | 65 | female | 1 | 92 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.4 | true | MSS | 2026-03-15T05:35:58.884370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273717 | REC_0008245 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 13.4 | 68 | female | 0 | 15 | 5.2 | 2 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:58.884606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588536 | REC_0008246 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 9.2 | 67 | female | 1 | 13 | 4.9 | 0 | alectinib 600 mg BID | 37.2 | true | MSS | 2026-03-15T05:35:58.884836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710070 | REC_0008247 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 4.5 | 61 | female | 0 | 42 | 5.5 | 2 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:35:58.885070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993930 | REC_0008248 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 30 | 18.3 | 54 | male | 0 | 11 | 2.9 | 0 | sotorasib 960 mg daily | 20.8 | true | MSI-H | 2026-03-15T05:35:58.885306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663281 | REC_0008249 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.2 | 63 | male | 0 | 15 | 6.6 | 8 | sotorasib 960 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:58.885542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923894 | REC_0008250 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 12.9 | 58 | female | 0 | 20 | 6 | 1 | pembrolizumab 200 mg q3w | 32.4 | false | MSS | 2026-03-15T05:35:58.885776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198426 | REC_0008251 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.6 | 55 | female | 1 | 29 | 6.5 | 3 | osimertinib 80 mg daily | 31.3 | false | MSI-H | 2026-03-15T05:35:58.886010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294488 | REC_0008252 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 71 | male | 2 | 24 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSS | 2026-03-15T05:35:58.886242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986846 | REC_0008253 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 9.1 | 71 | female | 0 | 18 | 5.6 | 1 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:58.886473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636182 | REC_0008254 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 7.9 | 58 | female | 0 | 16 | 5.6 | 2 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:58.886704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691744 | REC_0008255 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 2.9 | 67 | female | 0 | 57 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:58.886932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468126 | REC_0008256 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 17.7 | 56 | female | 1 | 19 | 5.6 | 6 | osimertinib 80 mg daily | 14 | false | MSI-H | 2026-03-15T05:35:58.887209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295052 | REC_0008257 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 6.5 | 67 | male | 1 | 0 | 5.2 | 1 | alectinib 600 mg BID | 17.7 | true | MSS | 2026-03-15T05:35:58.887445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500300 | REC_0008258 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 8 | 13.6 | 73 | female | 3 | 22 | 4.2 | 1 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:58.887679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492022 | REC_0008259 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 11.2 | 66 | female | 1 | 17 | 6.3 | 1 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:58.887911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386932 | REC_0008260 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 11.7 | 87 | female | 1 | 11 | 6.8 | 4 | sotorasib 960 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:58.888224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665340 | REC_0008261 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13.2 | 65 | male | 1 | 15 | 3.7 | 2 | alectinib 600 mg BID | 21.7 | true | MSI-H | 2026-03-15T05:35:58.888472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973376 | REC_0008262 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 15.8 | 75 | female | 2 | 13 | 6.4 | 9 | sotorasib 960 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:58.888706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823362 | REC_0008263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.3 | 54 | female | 0 | 12 | 4.4 | 8 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:58.888942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161451 | REC_0008264 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.5 | 69 | female | 1 | 27 | 6 | 3 | entrectinib 600 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:58.889175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953258 | REC_0008265 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 3.7 | 71 | male | 1 | 18 | 6 | 1 | sotorasib 960 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:58.889409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655134 | REC_0008266 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 8.7 | 79 | female | 1 | 12 | 5.4 | 1 | pembrolizumab 200 mg q3w | 21.2 | true | MSS | 2026-03-15T05:35:58.889636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528820 | REC_0008267 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16.2 | 70 | female | 2 | 8 | 3.8 | 2 | sotorasib 960 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:58.889875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993505 | REC_0008268 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 14 | 5.5 | 68 | male | 0 | 63 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:35:58.890115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424129 | REC_0008269 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10.3 | 62 | male | 0 | 18 | 7.6 | 2 | sotorasib 960 mg daily | 19 | false | MSS | 2026-03-15T05:35:58.890564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246580 | REC_0008270 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.9 | 65 | female | 0 | 8 | 7 | 5 | sotorasib 960 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.890815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619766 | REC_0008271 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 10.8 | 77 | female | 1 | 15 | 6.3 | 0 | osimertinib 80 mg daily | 54.2 | false | MSS | 2026-03-15T05:35:58.891062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600747 | REC_0008272 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.6 | 58 | male | 1 | 36 | 5.6 | 1 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:58.891297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202191 | REC_0008273 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 10.6 | 72 | female | 2 | 19 | 3 | 1 | sotorasib 960 mg daily | 22 | false | MSI-H | 2026-03-15T05:35:58.891533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664150 | REC_0008274 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 7.8 | 85 | female | 1 | 19 | 4.8 | 6 | pembrolizumab 200 mg q3w | 14.6 | true | MSS | 2026-03-15T05:35:58.891763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428057 | REC_0008275 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 2.1 | 71 | female | 2 | 83 | 4.2 | 5 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:58.891991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323250 | REC_0008276 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 9.1 | 66 | female | 0 | 11 | 8.4 | 6 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:58.892276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321692 | REC_0008277 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.9 | 64 | female | 0 | 16 | 6.3 | 2 | alectinib 600 mg BID | 10.2 | true | MSI-H | 2026-03-15T05:35:58.892520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650239 | REC_0008278 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 3.9 | 74 | female | 1 | 35 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:58.892764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273024 | REC_0008279 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.6 | 45 | male | 0 | 3 | 5.2 | 1 | osimertinib 80 mg daily | 25.9 | false | MSS | 2026-03-15T05:35:58.893019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554849 | REC_0008280 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.8 | 67 | female | 0 | 9 | 5.4 | 1 | sotorasib 960 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:35:58.893272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986706 | REC_0008281 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.2 | 76 | female | 1 | 59 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:58.893525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541151 | REC_0008282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.2 | 61 | female | 1 | 8 | 6.5 | 7 | entrectinib 600 mg daily | 14 | true | MSI-H | 2026-03-15T05:35:58.893868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308103 | REC_0008283 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 17 | 12.2 | 65 | female | 0 | 6 | 5.1 | 0 | osimertinib 80 mg daily | 36.5 | false | MSS | 2026-03-15T05:35:58.894115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525494 | REC_0008284 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.6 | 74 | female | 2 | 14 | 5.6 | 2 | alectinib 600 mg BID | 25.3 | true | MSS | 2026-03-15T05:35:58.894349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461747 | REC_0008285 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.8 | 51 | male | 0 | 17 | 5.3 | 7 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:58.894583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869695 | REC_0008286 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 36 | 13.3 | 63 | female | 1 | 9 | 5.5 | 2 | osimertinib 80 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:58.894818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199847 | REC_0008287 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 19.7 | 79 | female | 1 | 9 | 4.2 | 2 | entrectinib 600 mg daily | 26.2 | false | MSI-H | 2026-03-15T05:35:58.895049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826003 | REC_0008288 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 13 | 65 | female | 1 | 18 | 4.6 | 2 | osimertinib 80 mg daily | 18.2 | false | MSS | 2026-03-15T05:35:58.895283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422785 | REC_0008289 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 13.6 | 67 | female | 0 | 16 | 5.5 | 0 | osimertinib 80 mg daily | 20.9 | false | MSI-H | 2026-03-15T05:35:58.895515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960861 | REC_0008290 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 2.2 | 72 | female | 1 | 12 | 2.1 | 1 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:58.895746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171325 | REC_0008291 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15 | 61 | male | 0 | 23 | 6.4 | 6 | alectinib 600 mg BID | 18.5 | false | MSS | 2026-03-15T05:35:58.895984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897406 | REC_0008292 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.4 | 69 | female | 1 | 17 | 5 | 5 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:58.896266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117415 | REC_0008293 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 9.6 | 64 | male | 0 | 25 | 6.3 | 1 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.896501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634685 | REC_0008294 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 14.8 | 70 | female | 3 | 19 | 6.9 | 1 | osimertinib 80 mg daily | 17.5 | true | MSS | 2026-03-15T05:35:58.896732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817211 | REC_0008295 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 15 | 46 | male | 0 | 2 | 5.2 | 0 | sotorasib 960 mg daily | 26.7 | true | MSI-H | 2026-03-15T05:35:58.897021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990923 | REC_0008296 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.2 | 84 | female | 2 | 28 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:58.897254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983133 | REC_0008297 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 8.8 | 69 | male | 0 | 11 | 3.7 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.897489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444407 | REC_0008298 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 13 | 65 | male | 0 | 11 | 5.2 | 0 | alectinib 600 mg BID | 19.7 | true | MSS | 2026-03-15T05:35:58.897724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976908 | REC_0008299 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.8 | 70 | female | 1 | 43 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:58.897951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274006 | REC_0008300 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 9.2 | 71 | female | 1 | 24 | 5.4 | 0 | alectinib 600 mg BID | 22.4 | true | MSS | 2026-03-15T05:35:58.898180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.